Unique ID issued by UMIN | UMIN000040109 |
---|---|
Receipt number | R000045732 |
Scientific Title | Effect of Daily Ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study |
Date of disclosure of the study information | 2020/04/08 |
Last modified on | 2021/10/12 11:31:29 |
Effect of Daily Ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study
Effect of Daily Ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction
Effect of Daily Ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study
Effect of Daily Ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction
Japan |
Healthy adults
Not applicable | Adult |
Others
NO
To prove clinical benefits associated with 12 weeks daily ingestion of tea containing citrus ingredients on abdominal visceral fat area reduction, in a randomized, double-blind, placebo-controlled, parallel group comparison study.
Safety,Efficacy
Confirmatory
Pragmatic
Change in the visceral fat area after 12 weeks of ingestion.
Abdominal subcutaneous fat area, abdominal total fat area, TC, LDL-C, HDL-C, TG, LDL/HDL, body weight, body fat percentage, BMI, lean body mass, muscle mass, blood cGMP, prothrombin time, cytokine, grip strength, leg strength.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
YES
No need to know
2
Treatment
Food |
Daily ingestion of 13.6 g instant green tea for 12 weeks.
Daily ingestion of 13.6 g instant barley tea 12 weeks.
30 | years-old | <= |
75 | years-old | > |
Male and Female
1. Subjects whose LDL-C is more than 100 mg/dl and less than 140 mg/dl.
2. Subjects whose BMI is more than 23 kg/m 2 and less than 30 kg/m 2 .
3. Subjects who agree to participate in this study with a written informed consent.
1. Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia and/or diabetes.
2. Pacemaker or defibrillator users.
3. Subject who disagree to cooperate with grip strength test and leg strength test at the time of screening test.
4. Subjects with familial hypercholesterolemia.
5. Subjects whose fasting blood glucose values are more than 126 mg/dl.
6. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
7. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
8. Subjects with unusually high and/or low blood pressure and/or abnormal physical data and hematological data.
9. Subjects with severe anemia.
10. Pre- or post-menopausal women complaining of obvious physical changes.
11. Subjects s who regularly drink green tea.
12. Subjects who has high caffeine sensitivity.Subjects who are at risk of having allergic reactions to drugs or foods.
13. Subjects who has high caffeine sensitivity.
14. Subjects who regularly take medicine, functional foods, and/or supplements which would affect lipid metabolism.
15. Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism.
16. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
17. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks, or blood components within 2 weeks, prior to the current study.
18. Pregnant or lactating women or women who expect to be pregnant during this study.
19. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study.
20. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
60
1st name | Jun |
Middle name | |
Last name | NISHIHIRA |
Hokkaido Information University
Department of Medical Management and Informatics
069-8585
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
011-385-4411
nishihira@do-johodai.ac.jp
1st name | Jun |
Middle name | |
Last name | NISHIHIRA |
Hokkaido Information University
Health Information Science Center
069-8585
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
011-385-4430
nishihira@do-johodai.ac.jp
Hokkaido Information University
Toyota Motor Corporation
Profit organization
Japan
Bioresource and Bioenvironment Kyushu University
The ethics committee of Hokkaido Information University
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
011-385-4411
soumu@do-johodai.ac.jp
NO
北海道情報大学 保健センター(北海道)
2020 | Year | 04 | Month | 08 | Day |
Unpublished
https://www.nature.com/articles/s41598-021-98612-6
60
Main results already published
2020 | Year | 01 | Month | 22 | Day |
2020 | Year | 01 | Month | 22 | Day |
2020 | Year | 06 | Month | 24 | Day |
2020 | Year | 10 | Month | 17 | Day |
2020 | Year | 04 | Month | 08 | Day |
2021 | Year | 10 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045732